MedinCell S.A.·Healthcare

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced its participation at the TD Cowen 46th Annual Healthcare Conference, which will take place March 2-4, 2026 in Boston. The Company will present on Tuesday, March 3, 2026, at 1:50pm ET. Investor meetings with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may.

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full‑year 2025 results: About UZEDY® 2025 net sales reached $191 million, including $55 million in the fourth quarter Teva's initial 2026 net sales outlook is in the range of $250 - $280 million Medincell receives mid‑to high‑single-digit royalties on UZEDY® net sales and is eligible for up to $105.
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
Healthcare
Biotechnology
131
2021-01-05
0.98